Aminotriazolopyridines as kinase inhibitors

US10913738B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Junqing Guo · Princeton, US
• Amy C. Hart · Ewing, US
• John E. Macor · Guilford, US
• Michael E. Mertzman · New Hope, US
• William J. Pitts · Newtown, US
• Steven H. Spergel · Warrington, US
• Scott Hunter Watterson · Pennington, US
• Murugaiah Andappan Murugaiah Subbaiah · Komangalam, IN
• Jie Chen · Houston, US
• Carolyn Diane Dzierba · Middletown, US
• Guanglin Luo · Newtown, US
• Jianliang Shi · Furlong, US
• Sing-Yuen Sit · Meriden, US

Key dates

• Filing date: Feb 12, 2018
• Grant date: Feb 9, 2021
• Expiry date: Feb 12, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F9/6561
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds having formula (I) (IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein: (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).